0.09 -0.002 (-2.17%) | 10-05 09:57 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.1 | 1-year : | 0.1 |
Resists | First : | 0.09 | Second : | 0.09 |
Pivot price | 0 | |||
Supports | First : | 0.09 | Second : | 0.07 |
MAs | MA(5) : | 0 | MA(20) : | 0 |
MA(100) : | 0 | MA(250) : | 0 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 0 | D(3) : | 0 |
RSI | RSI(14): 0 | |||
52-week | High : | 0.09 | Low : | 0.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CYTR ] has closed Bollinger Bands are 0% narrower than normal.
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Mon, 26 Sep 2022
CytRx guns for a reset, rebranding as LadRx after a tough few years and a CEO change in January - FiercePharma
Thu, 18 Jun 2015
Sangamo Therapeutics (SGMO) Stock Price, News & Analysis - MarketBeat
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
OTC
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |